Ex Vivo Drug Response Platform From KYAN Shows Clinical Utility in Non-Hodgkin Lymphoma Patients
SINGAPORE, July 28, 2025 / EINPresswire.com / -- A prospective clinical study published in JCO Precision Oncology, a journal of the American Society of Clinical Oncology (ASCO), confirms that KYAN Technologies' Optim.AI™ platform (Quadratic Phenotypic Optimization Platform, or QPOP) accurately predicts clinical response in relapsed/refractory non-Hodgkin lymphoma (R/R-NHL), including hard-to-treat subtypes where genomic testing often offers limited guidance.
This prospective clinical validation study, conducted in 117 patients across two tertiary cancer centers, represents the largest published cohort to date using an ex vivo functional precision medicine platform in lymphoma. The results demonstrated meaningful clinical utility, reporting both objective response rates (ORR) and Kaplan-Meier survival outcomes, with significantly longer progression-free survival (PFS) in patients treated with combinations prioritized by the platform. The study showed that functionally guided therapies delivered not just predictive concordance, but measurable clinical benefit in a real-world setting.
Key study findings:
• 74.5 percent test accuracy in predicting clinical response
• 59 percent ORR in patients treated with platform-guided combinations
• Three-fold improvement in PFS compared to prior treatment line
• Two-year survival analysis showed a statistically significant benefit over salvage therapy (P = 0.0191)
'This study reinforces the scientific rigor behind the platform by showing we can deliver reproducible, clinically concordant results across a large cohort of real patient samples,' said Edward K. Chow, PhD, KYAN Technologies' Chief Scientific Officer. 'We're especially grateful to the essential contributions of our clinical collaborators at the National University of Singapore (NUS), National University Hospital (NUH), and Singapore General Hospital (SGH). Their guidance, insights and commitment helped shape a platform that delivers timely, reliable, and actionable guidance for both physicians and patients.'
Optim.AI™ directly measures how live tumor cells respond to therapy. Using a proprietary experimental design, the platform tests hundreds of clinically relevant drug treatments at once, including standard-of-care regimens, off-label therapies with known safety profiles, and novel options, and ranks them based on predicted treatment response. This functional, patient-specific readout provides oncologists with real-time guidance tailored to the biology of each tumor.
'This study marks a defining milestone in Optim.AI™'s journey toward clinical adoption. With our clinical and analytical validation now published in a peer-reviewed journal, we're positioned to scale the platform in the U.S., starting with CLIA deployment and expanding through partnerships with leading clinicians and institutions,' said Hugo Saavedra, Chief Executive Officer of KYAN Technologies.
The results underscore the broader potential of functional precision medicine to inform treatment decisions and combination design across oncology. By capturing how each patient's tumor responds to a breadth of drug regimens, Optim.AI™ not only guides clinical care but also offers insights that can support off-label strategy, clinical trial selection, and future drug development.
About KYAN Technologies
KYAN Technologies is a functional precision oncology company accelerating the discovery and deployment of effective cancer treatments. Its proprietary platform, Optim.AI™, uses ex vivo testing and combinatorial analytics to generate phenotypic response data from patient-derived tumor samples. This approach provides a clinically actionable layer of insight that complements genomic and transcriptomic tools.
Optim.AI™ supports both patient care and drug development, helping clinicians identify tailored treatment options and enabling biopharma partners to prioritize combination strategies, select indications, and design smarter trials. Headquartered in Singapore, KYAN is expanding its U.S. presence to advance clinical deployment and strategic collaborations across oncology research and care.
For media inquiries contact:
Sudha Sruthi, Corporate Development
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Old Trump speech falsely linked to South Korea trade deal
Social media posts have recirculated an old video of US President Donald Trump and falsely presented it as depicting him calling South Korean leader Lee Jae Myung a "bad negotiator" after their countries agreed a trade deal. The clip in fact shows Trump criticising then president Barack Obama as he launched his presidential campaign in June 2015. "Trump mocks Lee Jae Myung as a bad negotiator," reads a Korean-language post featuring the clip on Naver Band, a South Korean forum, on July 31, 2025. "[Trump] mocked Lee as soon as the tariff negotiations finished. [Lee] has become a total pushover," it continues. The video shows Trump saying, "The people negotiating don't have a clue. Our president doesn't have a clue. He's a bad negotiator." But its Korean subtitles mistranslate "our president" as "their president". The clip was also shared in similar posts on multiple right-wing South Korean circles on Facebook, as well as on YouTube. "The way that fool Lee acted as he did, no wonder he is being mocked," read a comment on one of the posts. Another said: "An international embarrassment to be used like that, then mocked by the US president." Under the trade deal, the United States will impose a 15 percent tariff on South Korean imports -- down from the previously threatened 25 percent -- in exchange for $350 billion in South Korean investments in US industries and $100 billion in energy purchases (archived link). A keyword search on Google found the clip corresponds to a part of a speech Trump gave on June 16, 2015, when he announced his bid for the presidency (archived link). At around the 18:50 mark of the speech posted in full by CSPAN, Trump makes the comment: "The people negotiating don't have a clue. Our president doesn't have a clue. He's a bad negotiator." This was part of a broader tirade against the Obama administration's trade and foreign policies. Trump then references a prisoner swap involving US soldier Bowe Bergdahl to illustrate his criticism of Obama's negotiating skills. Bergdahl was a US Army sergeant who was captured by the Taliban in 2009 after walking off his post in Afghanistan and was released in 2014 in exchange for five Taliban detainees held at Guantanamo Bay (archived link). "We get Bergdahl. We get a traitor. We get a no-good traitor, and they get the five people that they wanted for years, and those people are now back on the battlefield trying to kill us. That's the negotiator we have," Trump said. A full transcript of the speech published by Time magazine also shows Trump was referring to Obama (archived link). Nowhere in the video or transcript does Trump mention South Korea or Lee Jae Myung. AFP has previously debunked similar instances of Trump remarks and social media posts being misrepresented as references to South Korea.
Yahoo
4 minutes ago
- Yahoo
Those who invested in Fiamma Holdings Berhad (KLSE:FIAMMA) five years ago are up 134%
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But when you pick a company that is really flourishing, you can make more than 100%. For example, the Fiamma Holdings Berhad (KLSE:FIAMMA) share price has soared 112% in the last half decade. Most would be very happy with that. With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. Over half a decade, Fiamma Holdings Berhad managed to grow its earnings per share at 15% a year. This EPS growth is reasonably close to the 16% average annual increase in the share price. That suggests that the market sentiment around the company hasn't changed much over that time. Rather, the share price has approximately tracked EPS growth. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Dive deeper into the earnings by checking this interactive graph of Fiamma Holdings Berhad's earnings, revenue and cash flow. What About The Total Shareholder Return (TSR)? We've already covered Fiamma Holdings Berhad's share price action, but we should also mention its total shareholder return (TSR). The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. Fiamma Holdings Berhad's TSR of 134% for the 5 years exceeded its share price return, because it has paid dividends. A Different Perspective While it's never nice to take a loss, Fiamma Holdings Berhad shareholders can take comfort that their trailing twelve month loss of 3.6% wasn't as bad as the market loss of around 6.1%. Longer term investors wouldn't be so upset, since they would have made 19%, each year, over five years. It could be that the business is just facing some short term problems, but shareholders should keep a close eye on the fundamentals. Before forming an opinion on Fiamma Holdings Berhad you might want to consider these 3 valuation metrics. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Malaysian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Some May Be Optimistic About Nestlé (Malaysia) Berhad's (KLSE:NESTLE) Earnings
The market was pleased with the recent earnings report from Nestlé (Malaysia) Berhad (KLSE:NESTLE), despite the profit numbers being soft. However, we think the company is showing some signs that things are more promising than they seem. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Zooming In On Nestlé (Malaysia) Berhad's Earnings As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'. That means a negative accrual ratio is a good thing, because it shows that the company is bringing in more free cash flow than its profit would suggest. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". Over the twelve months to June 2025, Nestlé (Malaysia) Berhad recorded an accrual ratio of -0.20. Therefore, its statutory earnings were very significantly less than its free cashflow. In fact, it had free cash flow of RM712m in the last year, which was a lot more than its statutory profit of RM400.0m. Nestlé (Malaysia) Berhad's free cash flow improved over the last year, which is generally good to see. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Our Take On Nestlé (Malaysia) Berhad's Profit Performance As we discussed above, Nestlé (Malaysia) Berhad's accrual ratio indicates strong conversion of profit to free cash flow, which is a positive for the company. Because of this, we think Nestlé (Malaysia) Berhad's underlying earnings potential is as good as, or possibly even better, than the statutory profit makes it seem! Unfortunately, though, its earnings per share actually fell back over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. Every company has risks, and we've spotted 1 warning sign for Nestlé (Malaysia) Berhad you should know about. This note has only looked at a single factor that sheds light on the nature of Nestlé (Malaysia) Berhad's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
